Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI045207-005
Application #
2296096
Study Section
Project Start
1994-05-27
Project End
1999-05-30
Budget Start
1996-06-10
Budget End
1997-05-30
Support Year
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Iyengar, Sujatha; Schwartz, David H (2011) Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis. AIDS Res Hum Retroviruses 27:519-23
de Bruyn, Guy; Hudgens, Michael G; Sullivan, Patrick S et al. (2005) Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 39:499-501
Lee, Deborah; Graham, Barney S; Chiu, Ya-Lin et al. (2004) Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190:903-7
Gilbert, P B; Chiu, Y-L; Allen, M et al. (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-47
Allen, M; Israel, H; Rybczyk, K et al. (2001) Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses 17:667-74
Wright, P F; Lambert, J S; Gorse, G J et al. (1999) Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis 180:1080-8
McElrath, M J; Siliciano, R F; Weinhold, K J (1997) HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Hum Retroviruses 13:211-6